Prophase Labs

Prophase Labs Debt/EBITDA

The Total Debt to EBITDA Ratio of Prophase Labs (PRPH) as of Nov 1, 2026 is -0.48. In the previous year, Total Debt to EBITDA Ratio was -0.64 — a change of -24.93% (higher).

Debt/EBITDA

-0.48

YoY

-24.93%

Last updated:

Total Debt to EBITDA Ratio of Prophase Labs is 2025 -0.48 . Total Debt to EBITDA Ratio of Prophase Labs was 2024 -0.64 . It decreases by -24.93% higher compared to the previous year.

The Prophase Labs Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-2.20 USD
Jan 1, 2019
-0.29 USD
Jan 1, 2020
-3.71 USD
Jan 1, 2021
1.52 USD
Jan 1, 2022
0.29 USD
Jan 1, 2023
-0.85 USD
Jan 1, 2024
-0.64 USD
Jan 1, 2025
-0.48 USD
The Prophase Labs Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.48-24.93%
-0.64-25.51%
-0.85-389.49%
0.29-80.60%
1.52-141.03%
-3.71+1,196.13%
-0.29-86.99%
-2.20—
0.00-100.00%
-0.56+37.15%
-0.41+3,101.97%
-0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prophase Labs Stock analysis

What does Prophase Labs do? ProPhase Labs, Inc. generates revenue through the sale of over-the-counter consumer healthcare products and dietary supplements. The company develops and markets TK Supplements, featuring LEGENDZ XL for male sexual enhancement, TRIPLE EDGE XL for daily energy and stamina, and SUPER PROSTAFLOW plus for prostate and urinary health. ORXx Complete, a dietary supplement, and ORXx cough/cold drops are also sold to national wholesalers, distributors, and retail chains including pharmacies and mass merchandise stores. The firm targets health-conscious consumers seeking natural solutions through its OTC drug and supplement lines. Its products are distributed via national wholesalers and retailers such as independent and chain drugstores, food stores, and mass merchandise outlets. ProPhase Labs focuses on direct sales to these established retail segments without third-party branding or partnerships. Revenue streams are derived from the consistent demand for male enhancement, energy, and health supplements within the OTC market. The company's product portfolio caters specifically to customers interested in natural health products, with no additional services or digital platforms beyond physical product sales. Prophase Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prophase Labs stock

Total Debt to EBITDA Ratio of Prophase Labs is -0.48 in 2025.

Total Debt to EBITDA Ratio of Prophase Labs changed from -0.64 to -0.48, representing a -24.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Prophase Labs since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Prophase Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Prophase Labs

All Key Metrics — Prophase Labs